VA study evaluates quality indicators for hormone therapy in menopausal women
(Wolters Kluwer Health) Improvements are needed in VA's prescribing of hormone therapy for menopausal women veterans, concludes a study in the Journal for Healthcare Quality, the peer-reviewed journal of the National Association for Healthcare Quality. The journal is published in the Lippincott portfolio by Wolters Kluwer.
FRIDAY, Oct. 18, 2019 -- Longer use of estrogen hormone therapy is associated with higher cognitive status in late life, according to a study published online Oct. 14 in Menopause. Joshua M. Matyi, from Utah State University in Logan, and colleagues...
Publication date: November 2019Source: The Lancet Diabetes &Endocrinology, Volume 7, Issue 11Author(s): Susan R Davis
PMID: 31612748 [PubMed - in process]
A study published inMenopause suggests hormone therapy may improve cognitive function and brain health in menopausal women.MedicalXpress
Publication date: Available online 14 October 2019Source: Case Reports in Women's HealthAuthor(s): Loukas Athanasiadis, Dimitrios G. Goulis
Conclusions: Acupuncture significantly alleviated menopause symptoms for at least 3 months, but not hot flushes. Breast cancer patients concerned about the adverse effects of hormone therapy could consider acupuncture as an alternative. Additional acupuncture at 3 months after the initial treatment course could be considered. A large-scale study may help to define the optimal guideline for this issue. PMID: 31612733 [PubMed - as supplied by publisher]
ConclusionFurther studies are needed to elucidate the nature of the association between menopause, sleep and persistent pain syndromes, such as FM, showing the role of hormone therapy in prospective placebo ‐controlled trials.
Waseem Abbas, Ranga Raju RaoIndian Journal of Cancer 2019 56(4):293-296Adjuvant ovarian suppression, on addition to chemotherapy, reduces the risk of breast cancer in pre-menopausal women after surgery and adjuvant hormonal therapy. Suppression of Ovarian Function Trial (SOFT) and Tamoxifen and Exemestane Trial (TEXT) showed greater benefit with exemestane in high risk females in comparison to Tamoxifen. Ovarian Function Suppression (OFS) and exemestane became the standard of care, with 30% patients experiencing grade 3 and more side effects. Much higher benefit was seen in high risk group. But there are concerns about inc...
Introduction: Recent evidence demonstrates that women with myotonic dystrophy type 1 are at increased risk of reproductive organ tumors. However, studies of reproductive cancer risk factors in those patients are lacking.Methods: Using questionnaires, we collected and analyzed personal history information related to cancer risk factors from women enrolled in a UK and US registry for myotonic dystrophy (dystrophia myotonica; DM) patients.Results: The survey was completed by 242 DM type 1 (DM1) and 44 DM type 2 (DM2) women enrolled in the UK Registry (N = 124) and the US National Registry (N = 162). The mean age at DM1 diagno...